Your browser doesn't support javascript.
loading
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström, Emil; Steg, P Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Danchin, Nicolas; Diaz, Rafael; Goodman, Shaun G; Harrington, Robert A; Jukema, J Wouter; Liberopoulos, Evangelos; Marx, Nikolaus; McGinniss, Jennifer; Manvelian, Garen; Pordy, Robert; Scemama, Michel; White, Harvey D; Zeiher, Andreas M; Schwartz, Gregory G.
Afiliação
  • Hagström E; Uppsala University, Department of Medical Sciences, and Uppsala Clinical Research Center, Sweden (E.H.).
  • Steg PG; Department of Cardiology, Université de Paris, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), and INSERM U1148, France (P.G.S.).
  • Szarek M; Imperial College, Royal Brompton Hospital, London, UK (P.G.S.).
  • Bhatt DL; CPC Clinical Research (M. Szarek), University of Colorado School of Medicine, Aurora.
  • Bittner VA; Division of Cardiology (M. Szarek, G.G.S.), University of Colorado School of Medicine, Aurora.
  • Danchin N; State University of New York, Downstate Health Sciences University, Brooklyn (M. Szarek).
  • Diaz R; Department of Medicine, Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (D.L.B.).
  • Goodman SG; Division of Cardiovascular Disease, University of Alabama at Birmingham (V.A.B.).
  • Harrington RA; Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France (N.D.).
  • Jukema JW; Université Paris Descartes, France (N.D.).
  • Liberopoulos E; Estudios Cardiológicos Latino América, Instituto Cardiovascular de Rosario, Argentina (R.D.).
  • Marx N; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (S.G.G.).
  • McGinniss J; St. Michael's Hospital, University of Toronto, Ontario, Canada (S.G.G.).
  • Manvelian G; Stanford Center for Clinical Research, Department of Medicine, Stanford University, CA (R.A.H.).
  • Pordy R; Department of Cardiology, Leiden University Medical Center, the Netherlands (J.W.J.).
  • Scemama M; Netherlands Heart Institute, Utrecht (J.W.J.).
  • White HD; School of Medicine, National and Kapodistrian University of Athens, Greece (E.L.).
  • Zeiher AM; University Hospital, RWTH Aachen University, Germany (N.M.).
  • Schwartz GG; Regeneron Pharmaceuticals Inc, Tarrytown, NY (J.M., G.M., R.P.).
Circulation ; 146(9): 657-672, 2022 08 30.
Article em En | MEDLINE | ID: mdl-35770629
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Aterosclerose / Síndrome Coronariana Aguda / Anticolesterolemiantes Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Circulation Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Aterosclerose / Síndrome Coronariana Aguda / Anticolesterolemiantes Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Circulation Ano de publicação: 2022 Tipo de documento: Article